Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Induction of Leukaemia by 131I Treatment of Thyroid Carcinoma

Abstract

The records of 194 patients with thyroid carcinoma treated with 131I, representing all cases thus treated in Denmark from 1948 to 1972, were reviewed. Two cases of myeloid leukaemia were found compared with 0·097 expected cases of non-lymphocytic leukaemia (0·05 > P > 0·01). In 5 series of 131I treated thyroid carcinomata, 10 cases of myeloid leukaemia occurred in a total of 487 patients, corresponding to a frequency of leukaemia of about 2%. These findings appear to show that 131I treatment of thyroid carcinoma is associated with a certain risk of development of leukaemia. This risk must be considered when treatment of localized thyroid carcinoma is planned.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brincker, H., Hansen, H. & Andersen, A. Induction of Leukaemia by 131I Treatment of Thyroid Carcinoma. Br J Cancer 28, 232–237 (1973). https://doi.org/10.1038/bjc.1973.142

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1973.142

This article is cited by

Search

Quick links